Evidence map›Paper›PMID 24409314›Full record

ArticlePloS one2014

Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism.

Jianqun Liao, Feng Qian, Nana Tchabo, Paulette Mhawech-Fauceglia, Amy Beck, Zikun Qian, Xinhui Wang, Wendy J Huss, Shashikant B Lele, Carl D Morrison and 1 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01536054 (A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing ALVAC), which is not on this map. Cited by 230 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
230citing papers in PubMed, 2 pooled it
17.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01536054 phase1completednot on this map

A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing ALVAC(2)-NY-ESO-1(M)/TRICOM Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

TypeinterventionalSponsorRoswell Park Cancer InstituteRan2012 to 2015Enrolled7ConditionsRecurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IIA Fallopian Tube CancerArmsALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine, sirolimus, laboratory biomarker analysis, sargramostim
3 · Its place in the literature

Who cites it

230 citing papers in PubMed, 2 syntheses or guidelines pooled it, 363 citations in OpenAlex.

  1. Pooled it
  2. PGC1α-Mediated Metabolic Reprogramming Drives the Stemness of Pancreatic Precursor Lesions.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Pooled it
  3. Article
  4. Article
  5. Tumor-suppressive circRNAs in colorectal cancer spheroids and patients.Journal of the Chinese Medical Association : JCMA · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Loss ofOncotarget · 2025
    Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

170 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Jianqun LiaoDepartments of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York, United States of America ; Surgical Oncology, Roswell Park Cancer Institute, Buffalo, New York, United States of America.
Feng QianImmunology; Roswell Park Cancer Institute, Buffalo, New York, United States of America ; Center for Immunotherapy; Roswell Park Cancer Institute, Buffalo, New York, United States of America.
Nana TchaboAtlantic Health System Morristown/Overlook Medical Centers, Women's Cancer Center, Morristown and Summit, New Jersey, United States of America.
Paulette Mhawech-FaucegliaPathology, Roswell Park Cancer Institute, Buffalo, New York, United States of America.
Amy BeckCenter for Immunotherapy; Roswell Park Cancer Institute, Buffalo, New York, United States of America.
Zikun QianCenter for Immunotherapy; Roswell Park Cancer Institute, Buffalo, New York, United States of America.
Xinhui WangSurgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, United States of America.
Wendy J HussUrology Oncology, Roswell Park Cancer Institute, Buffalo, New York, United States of America ; Pharmacology & Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, United States of America.
Shashikant B LeleDepartments of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York, United States of America.
Carl D MorrisonPathology, Roswell Park Cancer Institute, Buffalo, New York, United States of America.
Kunle OdunsiDepartments of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York, United States of America ; Immunology; Roswell Park Cancer Institute, Buffalo, New York, United States of America ; Center for Immunotherapy; Roswell Park Cancer Institute, Buffalo, New York, United States of America.
Roswell Park Comprehensive Cancer Center · USMassachusetts General Hospital · USOverlook Medical Center · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
RPCI-UPCI Ovarian Cancer SPOREP50CA159981 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B. · 2013 to 2025
$19.6M
mTOR inhibition for generating memory T cells to enhance ovarian tumor immunityR01CA158318 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI ODUNSI, KUNLE, SHRIKANT, PROTUL · 2011 to 2015
$1.7M
NCI NIH HHS P30 CA016056NCI NIH HHS P50 CA159981NCI NIH HHS P50CA159981-01A1NCI NIH HHS R01 CA158318NCI NIH HHS R01CA158318-01A1
6 · The paper itself

Abstract

Cells with sphere forming capacity, spheroid cells, are present in the malignant ascites of patients with epithelial ovarian cancer (EOC) and represent a significant impediment to efficacious treatment due to their putative role in progression, metastasis and chemotherapy resistance. The exact mechanisms that underlie EOC metastasis and drug resistance are not clear. Understanding the biology of sphere forming cells may contribute to the identification of novel therapeutic opportunities for metastatic EOC. Here we generated spheroid cells from human ovarian cancer cell lines and primary ovarian cancer. Xenoengraftment of as few as 2000 dissociated spheroid cells into immune-deficient mice allowed full recapitulation of the original tumor, whereas >10(5) parent tumor cells remained non-tumorigenic. The spheroid cells were found to be enriched for cells with cancer stem cell-like characteristics such as upregulation of stem cell genes, self-renewal, high proliferative and differentiation potential, and high aldehyde dehydrogenase (ALDH) activity. Furthermore, spheroid cells were more aggressive in growth, migration, invasion, scratch recovery, clonogenic survival, anchorage-independent growth, and more resistant to chemotherapy in vitro. (13)C-glucose metabolic studies revealed that spheroid cells route glucose predominantly to anaerobic glycolysis and pentose cycle to the detriment of re-routing glucose for anabolic purposes. These metabolic properties of sphere forming cells appear to confer increased resistance to apoptosis and contribute to more aggressive tumor growth. Collectively, we demonstrated that spheroid cells with cancer stem cell-like characteristics contributed to tumor generation, progression and chemotherapy resistance. This study provides insight into the relationship between tumor dissemination and metabolic attributes of human cancer stem cells and has clinical implications for cancer therapy.

Indexed as

Drug Resistance, NeoplasmAldehyde DehydrogenaseAnimalsAntineoplastic AgentsCell Line, TumorCell MovementCell ProliferationCell Transformation, NeoplasticDisease Models, AnimalFemaleHumansHypoxiaImmunocompromised HostNeoplasm MetastasisNeoplastic Stem CellsOvarian NeoplasmsAldehyde DehydrogenaseAntineoplastic Agents

Identifiers

PMID24409314
PMCPMC3883678
OpenAlexW1983770566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.